| Item Type | Name |
|
Concept
|
Cardiovascular Diseases
|
|
Academic Article
|
Microalbuminuria: prognostic implications.
|
|
Academic Article
|
Predictors of renal and cardiovascular mortality in patients with non-insulin-dependent diabetes: a brief overview of microalbuminuria and insulin resistance.
|
|
Academic Article
|
Benefits of combination angiotensin-converting enzyme inhibitor and calcium antagonist therapy for diabetic patients.
|
|
Academic Article
|
Hypertension in patients with diabetes. Why is aggressive treatment essential?
|
|
Academic Article
|
Microalbuminuria: what is it? Why is it important? What should be done about it?
|
|
Academic Article
|
The Appropriate Blood Pressure Control in Diabetes (ABCD) Trial.
|
|
Academic Article
|
Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group.
|
|
Academic Article
|
Hypertension and diabetes: family physicians' pivotal role.
|
|
Academic Article
|
Choices and goals in the treatment of the diabetic hypertensive patient.
|
|
Academic Article
|
Angiotensin-converting enzyme inhibition to enhance vascular health--clinical and research models.
|
|
Academic Article
|
Evaluation and treatment of patients with systemic hypertension.
|
|
Academic Article
|
Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease.
|
|
Academic Article
|
Microalbuminuria in diabetes: focus on cardiovascular and renal risk reduction.
|
|
Academic Article
|
What have we learned from the current trials?
|
|
Academic Article
|
When does new onset diabetes resulting from antihypertensive therapy increase cardiovascular risk.
|
|
Academic Article
|
The importance of blood pressure control in the patient with diabetes.
|
|
Academic Article
|
How to adjust ACE inhibitors and ARBs in diabetes?
|
|
Academic Article
|
Are antihypertensive drugs used to maximally reduce cardiovascular risk in dialysis patients?
|
|
Academic Article
|
Control of blood pressure and other cardiovascular risk factors at different practice settings: outcomes of care provided to diabetic women compared to men.
|
|
Academic Article
|
Inclusion of albuminuria in hypertension and heart guidelines.
|
|
Academic Article
|
Is proteinuria a plausible target of therapy?
|
|
Academic Article
|
Cardiology patient page. Kidney failure and cardiovascular disease.
|
|
Academic Article
|
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.
|
|
Academic Article
|
Angiotensin receptor blockade and arterial compliance in chronic kidney disease: a pilot study.
|
|
Academic Article
|
Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial.
|
|
Academic Article
|
Angiotensin receptor blockers: therapeutic targets and cardiovascular protection.
|
|
Academic Article
|
Microalbuminuria and chronic kidney disease as risk factors for cardiovascular disease.
|
|
Academic Article
|
Clinical importance of microalbuminuria in diabetes and hypertension.
|
|
Academic Article
|
Slowing nephropathy progression: focus on proteinuria reduction.
|
|
Academic Article
|
Antihypertensive treatment with beta-blockers and the spectrum of glycaemic control.
|
|
Academic Article
|
The ADVANCE trial: further PROGRESS with HOPE.
|
|
Academic Article
|
Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.
|
|
Academic Article
|
Slowing the progression of diabetic nephropathy and its cardiovascular consequences.
|
|
Academic Article
|
Current perspectives on hypertension and metabolic syndrome.
|
|
Academic Article
|
Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Trandolapril Study.
|
|
Academic Article
|
Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.
|
|
Academic Article
|
Chronic kidney disease, prevalence of premature cardiovascular disease, and relationship to short-term mortality.
|
|
Academic Article
|
Advanced glycation end-product cross-link breakers. A novel approach to cardiovascular pathologies related to the aging process.
|
|
Academic Article
|
Effects of thiazolidinediones beyond glycaemic control.
|
|
Academic Article
|
The message for World Kidney Day 2009: hypertension and kidney disease--a marriage that should be prevented.
|
|
Academic Article
|
Glycemic control and cardiovascular disease in chronic kidney disease.
|
|
Academic Article
|
Should nephrologists use beta-blockers? A perspective.
|
|
Academic Article
|
The current state of RAAS blockade in the treatment of hypertension and proteinuria.
|
|
Academic Article
|
Gender disparity in outcomes of care and management for diabetes and the metabolic syndrome.
|
|
Academic Article
|
Monitoring and managing urinary albumin excretion: practical advice for primary care clinicians.
|
|
Academic Article
|
Are there effects of renin-angiotensin system antagonists beyond blood pressure control?
|
|
Academic Article
|
Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association.
|
|
Academic Article
|
The role of hyperglycaemia and the hypercoagulable state in the pathogenesis of cardiovascular events in diabetes mellitus: implications for hypertension management.
|
|
Academic Article
|
Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial.
|
|
Academic Article
|
Treatment and control of high blood pressure in adults.
|
|
Academic Article
|
24-hour ambulatory blood pressure in the ACCOMPLISH trial.
|
|
Academic Article
|
Lower blood pressure goals in high-risk cardiovascular patients: are they defensible?
|
|
Academic Article
|
Is it time for a cardiovascular primary prevention trial in the elderly?
|
|
Academic Article
|
Microalbuminuria: what is it? Why is it important? What should be done about it? An update.
|
|
Academic Article
|
Albuminuria and cardiovascular risk.
|
|
Academic Article
|
Cardiovascular risk modification in participants with coronary disease screened by the Kidney Early Evaluation Program.
|
|
Academic Article
|
Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP).
|
|
Academic Article
|
Beta-blockers in the treatment of hypertension: new data, new directions.
|
|
Academic Article
|
Hypertension in early-stage kidney disease: an update from the Kidney Early Evaluation Program (KEEP).
|
|
Academic Article
|
Plasma parathyroid hormone level and prevalent cardiovascular disease in CKD stages 3 and 4: an analysis from the Kidney Early Evaluation Program (KEEP).
|
|
Academic Article
|
EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome.
|
|
Academic Article
|
Pros and cons of aggressive blood pressure lowering in patients with type 2 diabetes.
|
|
Academic Article
|
Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors.
|
|
Academic Article
|
N-terminal prohormone brain natriuretic peptide as a predictor of cardiovascular disease and mortality in blacks with hypertensive kidney disease: the African American Study of Kidney Disease and Hypertension (AASK).
|
|
Academic Article
|
Influence of microalbuminuria in achieving blood pressure goals.
|
|
Academic Article
|
Cardiovascular protection for all individuals at high risk: evidence-based best practice.
|
|
Academic Article
|
ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension.
|
|
Academic Article
|
Are renin-angiotensin-aldosterone system blockers distinguishable based on cardiovascular and renal outcomes in nephropathy?
|
|
Academic Article
|
Management of hypertension in patients with diabetes: the place of angiotensin-II receptor blockers.
|
|
Academic Article
|
Lower blood pressure goals for cardiovascular and renal risk reduction: are they defensible?
|
|
Academic Article
|
Hypertension goals in advanced-stage kidney disease.
|
|
Academic Article
|
Dysglycemia predicts cardiovascular and kidney disease in the Kidney Early Evaluation Program.
|
|
Academic Article
|
Serum creatinine vs. albuminuria as biomarkers for the estimation of cardiovascular risk.
|
|
Academic Article
|
Prevention of microalbuminuria in patients with type 2 diabetes: what do we know?
|
|
Academic Article
|
Diabetes, the kidney, and cardiovascular risk. Preface.
|
|
Academic Article
|
Kidney dysfunction, cardiorespiratory fitness, and the risk of death in women.
|
|
Academic Article
|
National Kidney Foundation consensus conference on cardiovascular and kidney diseases and diabetes risk: an integrated therapeutic approach to reduce events.
|
|
Academic Article
|
Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association.
|
|
Academic Article
|
Prevalence of CKD and comorbid illness in elderly patients in the United States: results from the Kidney Early Evaluation Program (KEEP).
|
|
Academic Article
|
Malnutrition-inflammation modifies the relationship of cholesterol with cardiovascular disease.
|
|
Academic Article
|
Renal function and target organ damage in hypertension.
|
|
Academic Article
|
Renal outcomes in hypertensive Black patients at high cardiovascular risk.
|
|
Academic Article
|
Treatment of renal failure and blood pressure.
|
|
Academic Article
|
Preservation of renal function: the spectrum of effects by calcium-channel blockers.
|
|
Academic Article
|
Hypertension-related disease in African Americans. Factors underlying disparities in illness and its outcome.
|
|
Academic Article
|
Level of kidney function determines cardiovascular fate after coronary bypass graft surgery.
|
|
Academic Article
|
The kidney and cardiovascular risk--implications for management: a consensus statement from the European Society of Hypertension.
|
|
Academic Article
|
Pathogenesis and treatment of microalbuminuria in patients with diabetes: the road ahead.
|
|
Academic Article
|
Pediatrics: Masked hypertension: a risk factor in children with CKD.
|
|
Academic Article
|
Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial.
|
|
Academic Article
|
Obesity, blood pressure, and cardiovascular outcomes - Authors' reply.
|
|
Academic Article
|
Clinical guidelines: blood pressure goals in T2DM: a Latin American perspective.
|
|
Academic Article
|
Recognition and management of masked hypertension: a review and novel approach.
|
|
Academic Article
|
Systolic blood pressure and cardiovascular outcomes during treatment of hypertension.
|
|
Academic Article
|
The author replies.
|
|
Academic Article
|
The OSCAR for cardiovascular disease prevention in chronic kidney disease goes to blood pressure control.
|
|
Academic Article
|
Diabetic kidney disease: a report from an ADA Consensus Conference.
|
|
Academic Article
|
The role of aldosterone in the spectrum of cardiovascular and kidney disease risk: introduction.
|
|
Academic Article
|
Microalbuminuria as a risk predictor in diabetes: the continuing saga.
|
|
Academic Article
|
Renin inhibition in patients with chronic kidney disease: is it conclusively non-indicated?
|
|
Academic Article
|
Association of cognitive dysfunction with cardiovascular disease events in elderly hypertensive patients.
|
|
Academic Article
|
Dynamic resistant hypertension patterns as predictors of cardiovascular morbidity: a 4-year prospective study.
|
|
Academic Article
|
Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease.
|
|
Academic Article
|
Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
|
|
Academic Article
|
Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial.
|
|
Academic Article
|
In search for the 'sweet spot' for blood pressure level in diabetes.
|
|
Academic Article
|
Diabetic Cardiovascular Disease Predicts Chronic Kidney Disease Awareness in the Kidney Early Evaluation Program.
|
|
Academic Article
|
Cardiovascular disease in CKD in 2014: new insights into cardiovascular risk factors and outcomes.
|
|
Academic Article
|
Resting heart rate is associated with renal disease outcomes in patients with vascular disease: results of the ONTARGET and TRANSCEND studies.
|
|
Academic Article
|
Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial.
|
|
Academic Article
|
Cardiovascular Mortality in Patients With Type 2 Diabetes and Recent Acute Coronary Syndromes From the EXAMINE Trial.
|
|
Academic Article
|
From epidemiological transition to modern cardiovascular epidemiology: hypertension in the 21st century.
|
|
Academic Article
|
Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion.
|
|
Academic Article
|
The Implications of Blood Pressure Measurement Methods on Treatment Targets for Blood Pressure.
|
|
Academic Article
|
Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS.
|
|
Academic Article
|
Intensive Hemodialysis, Left Ventricular Hypertrophy, and Cardiovascular Disease.
|
|
Academic Article
|
Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: The EXAMINE trial.
|
|
Academic Article
|
Hypertension control and cardiovascular disease - Authors' reply.
|
|
Academic Article
|
Sodium/Glucose Cotransporter 2 Inhibitors in Patients With Diabetes Mellitus and Chronic Kidney Disease: Turning the Page.
|
|
Academic Article
|
The association of interdialytic blood pressure variability with cardiovascular events and all-cause mortality in haemodialysis patients.
|
|
Academic Article
|
Presence of Diabetes Does Not Mandate Lower Blood Pressure to Reduce Cardiovascular Events.
|
|
Academic Article
|
Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function.
|
|
Academic Article
|
Hyperuricemia, Acute and Chronic Kidney Disease, Hypertension, and Cardiovascular Disease: Report of a Scientific Workshop Organized by the National Kidney Foundation.
|
|
Academic Article
|
Diabetic Kidney Disease: A Determinant of Cardiovascular Risk in Type 1 Diabetes.
|
|
Academic Article
|
Hypertension.
|
|
Academic Article
|
Results of ACCORDIAN in ACCORD with lower blood pressure begetting lower mortality in patients with diabetes.
|
|
Academic Article
|
Controversies in the 2017 ACC/AHA Hypertension Guidelines: Who Can Be Eligible for Treatments Under the New Guidelines? - An Asian Perspective.
|
|
Academic Article
|
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
|
|
Academic Article
|
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups.
|
|
Academic Article
|
Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial.
|
|
Academic Article
|
Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial.
|
|
Academic Article
|
Fear of Lowering Cardiovascular Risk by Achieving Blood Pressure Goals: The Irrationality of Combination Therapy Avoidance.
|
|
Academic Article
|
Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial.
|
|
Academic Article
|
Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes.
|
|
Academic Article
|
Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial.
|
|
Academic Article
|
Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis.
|
|
Academic Article
|
The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial.
|
|
Academic Article
|
Influence of sex, age and race on coronary and heart failure events in patients with diabetes and post-acute coronary syndrome.
|
|
Academic Article
|
Intersection Between Chronic Kidney Disease and Cardiovascular Disease.
|
|
Academic Article
|
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.
|
|
Academic Article
|
Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results.
|
|
Academic Article
|
DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases.
|
|
Academic Article
|
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2022.
|
|
Academic Article
|
Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis.
|
|
Academic Article
|
The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trial.
|
|
Academic Article
|
Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study.
|
|
Academic Article
|
Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial.
|
|
Academic Article
|
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis.
|
|
Academic Article
|
Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria.
|
|
Academic Article
|
Early intervention and intensive management of patients with diabetes, cardiorenal, and metabolic diseases.
|
|
Academic Article
|
Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon-like peptide-1 receptor agonist use.
|
|
Academic Article
|
Albuminuria and Heart Failure: JACC State-of-the-Art Review.
|
|
Academic Article
|
Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: A post hoc analysis of the CREDENCE trial.
|
|
Academic Article
|
Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease.
|
|
Academic Article
|
Newer alternatives for resistant hypertension: Beyond 2022 paradigms.
|
|
Academic Article
|
Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial.
|
|
Grant
|
AASK Cohort Study
|
|
Academic Article
|
The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trials.
|
|
Academic Article
|
Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials.
|
|
Academic Article
|
Modifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With Finerenone.
|
|
Academic Article
|
Effect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient Populations.
|
|
Academic Article
|
Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria.
|